New agents for the treatment of acute myelogenous leukemia are discussed th
at reflect different treatment mechanisms. These include histone acetylatio
n, angiogenesis inhibition, protein kinase inhibitors, and a novel retinoid
. Efficacy and safety in phase I and phase II trials reviewed, as well as t
he problems involved in crossing over from treatment of solid tumors to blo
od disorders.